Conatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Conatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis
December 5, 2018 7:30 AM EST- Clinically Meaningful Improvements in Portal Hypertension in High Risk Compensated Cirrhosis Patients -
- Conference Call and Webcast Presentation at 8:30 a.m. ET Today -
SAN DIEGO, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) today announced top-line results from the companys Phase 2b ENCORE-PH clinical trial showing clinically meaningful treatment effects in compensated NASH cirrhosis patients at high risk of decompensation. The trials primary endpoint was change in mean hepatic venous pressure gradient (HVPG) from... More
